Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency
about
Management of acute attacks of hereditary angioedema: role of ecallantideCurrent pharmacotherapy of bradykinin-mediated angioedema.Anaesthesia Management of a Patient with Hereditary Angioedema with Prophylactic Administration of C1 Esterase Inhibitor: Case report and literature review.S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.Investigational drugs in phase I and phase II clinical trials for hereditary angioedema.
P2860
Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Ecallantide is a novel treatme ...... due to C1 inhibitor deficiency
@ast
Ecallantide is a novel treatme ...... due to C1 inhibitor deficiency
@en
type
label
Ecallantide is a novel treatme ...... due to C1 inhibitor deficiency
@ast
Ecallantide is a novel treatme ...... due to C1 inhibitor deficiency
@en
prefLabel
Ecallantide is a novel treatme ...... due to C1 inhibitor deficiency
@ast
Ecallantide is a novel treatme ...... due to C1 inhibitor deficiency
@en
P2860
P356
P1476
Ecallantide is a novel treatme ...... due to C1 inhibitor deficiency
@en
P2093
Henriette Farkas
Lilian Varga
P2860
P356
10.2147/CCID.S10322
P407
P577
2011-05-31T00:00:00Z